Merck Defends Actions Prior to Vioxx Recall - Part Two

This is the conclusion of a two-part article. For Part One, click here.

QUESTIONS AND ANSWERS Cont.

Mr. Frazier (continued): Another one of your questions was, in effect, what do we make of the naproxen issue in terms of the FDA warning letter? I want to say that it's important to understand exactly what that letter dealt with. It addressed three specific promotional activities. First, a specific set of speaker programs, a press release and then statements made by representatives at two medical meetings. It did not state that the agency believed that Vioxx caused cardiovascular events. …